Assessment of Serum Thrombomodulin in Patients with Systemic Lupus Erythematosus in Rheumatology Research Center

Akbarian, Mahmood; Gharibdoost, Farhad; Hadjaliloo, Mehrzad; Nadji, Abdolhadi; Jamshidi, Ahmad Reza; Shahram, Farhad; Akhlaghi, Masoomeh; Khosravi, Shahrzad; Almasi, Simin; Davatchi, Fereydoun
April 2009
Acta Medica Iranica;2009, Vol. 47 Issue 2, p97
Academic Journal
At present, some clinical presentations and serological parameters such as products of complement activation and elevation of autoantibodies (e.g. dsDNA antibodies), erythrocyte sedimentation rate (ESR), levels of C-reactive protein (CRP), or cytokines such as IL-2/IL-2 receptor, IL-6 and IL-10 are used as indirect serological markers with variable degrees of significance. To date, no specific serological parameter is available to assess disease activity in SLE. Soluble serum thrombomodulin is a new marker of endothelial cell injury and vasculitis. The objective of this study was to determine in vivo soluble thrombomodulin as a marker of disease activity in SLE patients and compare serum thrombomodulin in SEL patients with and without renal involvement and inactive SLE patients. Sixty-four patients fulfilling ACR criteria with proven SLE with different disease activities were tested for serum levels of Thrombomodulin and dsDNA by ELISA. C3, C4 and FANA were also measured by standard laboratory tests. The clinical disease activity was evaluated by the Systemic Lupus Erythematosus Activity Index (SLEDAI). Elevated soluble thrombomodulin had significant correlations with an increased ANA level (P= 0.037), decrease level of C3 (P =0.017), increase of SLEDAI (P=0.003) and strongly associated with renal involvement in SLE. Thrombomodulin level and Anti dsDNA in active patients with and without renal disease were higher than inactive patients. In SLE, serum thrombomodulin seems to be important marker for evaluation of disease activity.


Related Articles

  • Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. Vaglio, A.; Palmisano, A.; Ferretti, S.; Alberici, F.; Casazza, I.; Salvarani, C.; Buzio, C. // Rheumatology;Mar2008, Vol. 47 Issue 3, p315 

    Objectives. Chronic periaortitis (CP) is a rare disease with a potentially immune-mediated pathogenesis. The study aims to report the frequency and the clinical characteristics of peripheral inflammatory arthritis in a cohort of CP patients, and to review the literature regarding the association...

  • Diagnosis of Periprosthetic Joint Infection: The Threshold for Serological Markers. Alijanipour, Pouya; Bakhshi, Hooman; Parvizi, Javad // Clinical Orthopaedics & Related Research;Oct2013, Vol. 471 Issue 10, p3186 

    Background: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have recently been suggested as diagnostic criteria for periprosthetic joint infection (PJI) diagnosis. Thresholds for these markers should be reexamined since they have been determined arbitrarily. Questions/purposes:...

  • C1-inhibitor autoantibodies in SLE. Mészáros, T.; Füst, G.; Farkas, H.; Jakab, L.; Temesszentandrási, G.; Nagy, G.; Kiss, E.; Gergely, P.; Zeher, M.; Griger, Z.; Czirják, L.; Hóbor, R.; Haris, Á.; Polner, K.; Varga, L. // Lupus;Apr2010, Vol. 19 Issue 5, p634 

    The presence of anti-C1-inhibitor (anti-C1-INH) autoantibodies is a hallmark of acquired C1-inhibitor deficiency. However, only scarce data are available on their prevalence, diagnostic value, and/or significance in systemic lupus erythematosus (SLE). In a multicentre study, we determined the...

  • The relationship of inflammatory cytokines with asthma and obesity. Canöz, M.; Erdenen, F.; Uzun, H.; Müderrisoğlu, C.; Aydin, S. // Clinical & Investigative Medicine;Dec2008, Vol. 31 Issue 6, pE373 

    Objectives: Obesity is considered a risk factor for asthma. However, the mechanism that connects the two is not well understood. In this study we investigated the relationship between inflammatory cytokines and acute phase reactants in obesity, and asthma. Method: Asthmatic and control subjects...

  • The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Karkucak, Murat; Capkin, Erhan; Alver, Ahmet; Akyuz, Ayse; Kiris, Abdulkadir; Ak, Emel; Topbas, Murat; Tosun, Mehmet // Clinical Rheumatology;Mar2010, Vol. 29 Issue 3, p303 

    The aim of this study was to comparatively evaluate oxidative status of ankylosing spondylitis (AS) patients receiving anti-tumor necrosis factor (TNF) or non-steroid anti-inflammatory drugs (NSAID). Forty-seven patients with AS and 27 healthy controls were enrolled. Of these, 23 were on...

  • Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Romero-Sánchez, Consuelo; Robinson, William; Tomooka, Beren H.; Londoño, John; Valle-Oñate, Rafael; Feng Huang; Xiaohu Deng; Liyun Zhang; Chunhua Yang; Tak Yan Yu, David // Clinical Rheumatology;Nov2008, Vol. 27 Issue 11, p1429 

    Although most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much...

  • Endothelial Injury Markers With High-dose Intravenous Iron Therapy in Renal Failure. Borawski, Jacek; Gozdzikiewicz, Joanna; Abramowicz, Pawel; Naumnik, Beata; Mysliwiec, Michal // Clinical & Applied Thrombosis/Hemostasis;Oct2004, Vol. 10 Issue 4, p403 

    Endothelial injury is prevalent in patients with chronic renal failure (CRF) and may be exacerbated by commonly used intravenous (IV) iron therapy. The effects of high-dose IV iron sucrose treatment (200 mg daily in 250 mL of 0.9% saline, administered over 1 hour, median treatment duration 5...

  • Laboratory Tests in Rheumatology. Sachdeva, Saru; Colburn, Keith // Primary Care Reports;Sep2013, Vol. 19 Issue 9, p121 

    The article discusses various laboratory results and tests used for rheumatologic diseases. It says that at least 25% change in the concentrations of acute plasma reactants is noted in inflammatory conditions. It states that erythrocyte sedimentation rate (ESR) is a common inflammation marker....

  • In the Literature.  // Clinical Infectious Diseases;Apr2011, Vol. 52 Issue 7, piii 

    An introduction is presented in which the editor discusses about erythrocyte sedimentation rate and C-reactive protein.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics